PWMG
GTBP icon

Private Wealth Management Group’s GT Biopharma GTBP Stock Holding History

Private Wealth Management Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.79K Hold
20,000
– – ﹤0.01% 585
2026
Q1 		$8.16K Buy
+20,000
New +$10.9K ﹤0.01% 594

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Private Wealth Management Group's GTBP Position: Q2 2026 in Review

Private Wealth Management Group held its GT Biopharma (GTBP) position steady in Q2 2026 at 20,000 shares worth $9.79K. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Private Wealth Management Group first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Private Wealth Management Group held 20,000 shares of GT Biopharma worth $9.79K as of Q2 2026.
  • Private Wealth Management Group left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #585 holding.
  • Private Wealth Management Group first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.